NCT01476943|Completed
Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study
CTS
Belatacept in Renal Transplantation: Patterns of Use Analysis Using the Collaborative Transplant Study (CTS)
Loading search results
CTS
Belatacept in Renal Transplantation: Patterns of Use Analysis Using the Collaborative Transplant Study (CTS)
Sponsor study identifier
observational
72,392
0 countries
N/A
Study Start
March 31, 2012
Actual (reported)Primary Completion
April 30, 2018
Actual (reported)Study Completion
April 30, 2018
Actual (reported)The primary purpose is to describe the pattern of Belatacept use at the time of transplant and up to three years post-transplantation for all Belatacept treated patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 30, 2018
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 8, 2011
Actual (reported)November 22, 2011
Actual (reported)March 31, 2012
Actual (reported)April 30, 2018
Actual (reported)April 30, 2018
Actual (reported)The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by Cytomegalovirus (CMV) serostatus
At the time of transplantation
The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus
1 year post transplantation
The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus
2 year post transplantation
The number and percent of belatacept users overall, by Epstein-Barr Virus (EBV) serostatus and by CMV serostatus
3 year post transplantation
Extent of switches to or from Belatacept within three years post transplantation, and the temporal trend in switches post regulatory approval of Belatacept
At transplantation, 12 month, 24 month and 36 month post transplantation
Characteristics of Belatacept users vs. Calcineurin inhibitor (CNIs) users at transplantation
At the time of transplantation
Characteristics of those who switch to or from Belatacept vs. those who do not switch one year post-transplant
At transplantation and 12 month post transplantation
Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept or a CNI based regimen at the time of transplantation
Contact the study team to confirm eligibility.
Bristol-Myers Squibb
Bristol-Myers Squibb
72,392 participants (actual enrollment reported by the registry).
First Submitted
November 8, 2011
First Posted
November 22, 2011
Study Start
March 31, 2012
Actual (reported)Remote Ischemic Preconditioning in Neurological Death Organ Donors
Primary Completion
April 30, 2018
Actual (reported)Study Completion
April 30, 2018
Actual (reported)Last Updated
May 4, 2018
Record last verified: 2018-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: